|Articles|July 30, 2014
- NSCLC (Issue 3)
- Volume 3
- Issue 1
Adverse Events Associated With CO-1686
Author(s)Lecia V. Sequist, MD
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with CO-1686 for patients with non-small cell lung cancer (NSCLC).
Lecia V. Sequist, MD, medical oncologist, associate professor, Massachusetts General Hospital, Harvard Medical School, discusses adverse events (AEs) associated with the novel EGFR inhibitor CO-1686 for patients with non-small cell lung cancer (NSCLC).
View more on other next-generation therapies for NSCLC > >
Articles in this issue
over 11 years ago
Update on Next-Generation Therapies for NSCLCover 11 years ago
Cabozantinib Plus Erlotinib for Advanced EGFR-Mutant NSCLCover 11 years ago
<em>RICTOR</em> Amplification in Lung Cancerover 11 years ago
Peer Discussion on Maintenance Therapy in NSCLCover 11 years ago
Trials of Anti-PD-L1 in NSCLC Are Well Under WayRelated Content
Advertisement
